MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
APOAI 和动脉粥样硬化的巨噬细胞表达
基本信息
- 批准号:6760012
- 负责人:
- 金额:$ 33.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-07-01 至 2005-06-30
- 项目状态:已结题
- 来源:
- 关键词:apolipoprotein Eapolipoproteinsatherosclerosisblood lipoprotein metabolismbone marrow transplantationcellular pathologycholesterolcomplementary DNAdisease /disorder modelgene expressiongene targetinggene therapygenetically modified animalshigh density lipoproteinslaboratory mouseleukocyte activation /transformationlipid metabolismlipid transportlipoprotein lipaselow density lipoprotein receptormacrophagemodel design /developmentmolecular pathologytissue /cell culturevascular endothelium
项目摘要
DESCRIPTION: (adapted from abstract) Recruitment of monocyte/macrophages into
the subendothelial space is a mandatory step in the transition between vascular
health and atherosclerotic lesion formation. Accumulation of lipids within the
cytoplasm induces the transformation of macrophages into metabolically inert
foam cells. Efflux of cholesterol from the macrophages cannot only delay foam
cell formation but also activates reverse cholesterol transport. Apolipoprotein
(apo) AI is one of the major physiologic determinants of cholesterol efflux
from cells, but is not expressed by tissue macrophages. In previous studies,
the applicant has shown that macrophage production of apoE (another acceptor of
intracellular cholesterol) directly influences lesion formation in inbred
C57BL/6 mice. Dr. Fazio hypothesizes that, if given the ability to produce
apoAI, macrophages would be more efficient in getting rid of cholesterol and in
activating HDL metabolism. To this end, his group has produced several lines of
transgenic mice expressing the human apoAI under the control of a
macrophage-specific promoter. In addition, they have developed a viable method
for transduction of bone marrow with a retrovirus carrying the apoAI cDNA, and
shown that transplantation of transduced marrow into irradiated mice will
result in expression of apoAI from macrophages. The objectives of this research
program are: i) To create and characterize transgenic mice with the ability to
produce apoAI from the macrophage; ii) To evaluate the effect of macrophage
apoAI expression on lipids and atherosclerosis in C57BL/6 mice and in mice
lacking either the apoAI or the apoE gene; iii) To evaluate the effect of
macrophage apoAI in ACAT-1-/- mice, a model of free cholesterol toxicity and
inappropriate efflux; iv) To evaluate the feasibility of marrow transduction as
a method for ex vivo delivery of apoAI to the macrophage. These studies can be
expected to delineate the biology of foam cell formation and the importance of
cholesterol efflux in atherogenesis. Moreover, these studies may lay the basis
for a gene therapy approach to atherosclerosis.
描述:(改编自摘要)单核细胞/巨噬细胞招募至
内皮下间隙是血管与内皮细胞之间过渡的必要步骤,
健康和动脉粥样硬化病变形成。脂质在体内的积累
细胞质诱导巨噬细胞转化为代谢惰性细胞,
泡沫细胞胆固醇从巨噬细胞中流出不仅可以延缓泡沫形成,
细胞形成,而且还激活胆固醇逆向转运。载脂
(apo)AI是胆固醇流出的主要生理决定因素之一
从细胞,但不表达的组织巨噬细胞。在以前的研究中,
本申请人已经表明巨噬细胞产生apoE(apoE另一种受体)
细胞内胆固醇)直接影响近交系中病变的形成
c57 bl/6小鼠法齐奥博士假设,如果有能力产生
apoAI,巨噬细胞将更有效地摆脱胆固醇,
激活HDL代谢。为此,他的团队制作了几条线,
表达人apoAI的转基因小鼠在一种
巨噬细胞特异性启动子。此外,他们还开发了一种可行的方法,
用于用携带apoAI cDNA的逆转录病毒转导骨髓,和
表明将转导的骨髓移植到受辐射的小鼠中将
导致巨噬细胞表达apoAI。本研究的目标
i)创建和表征具有以下能力的转基因小鼠:
从巨噬细胞产生apoAI; ii)评估巨噬细胞的作用
载脂蛋白AI在C57 BL/6小鼠和小鼠脂质和动脉粥样硬化中的表达
缺乏apoAI或apoE基因; iii)评估apoAI或apoE基因的影响
ACAT-1-/-小鼠中的巨噬细胞apoAI,游离胆固醇毒性模型,
iv)评估骨髓转导作为治疗的可行性,
一种将apoAI离体递送至巨噬细胞的方法。这些研究可以
期望描绘泡沫细胞形成的生物学和
动脉粥样硬化形成中的胆固醇流出。此外,这些研究可能奠定了基础,
动脉粥样硬化的基因治疗方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SERGIO FAZIO其他文献
SERGIO FAZIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SERGIO FAZIO', 18)}}的其他基金
Functional and structural correlates of PCSK9 association with lipoproteins
PCSK9 与脂蛋白关联的功能和结构相关性
- 批准号:
9335438 - 财政年份:2016
- 资助金额:
$ 33.98万 - 项目类别:
Functional and structural correlates of PCSK9 association with lipoproteins
PCSK9 与脂蛋白关联的功能和结构相关性
- 批准号:
9155814 - 财政年份:2016
- 资助金额:
$ 33.98万 - 项目类别:
PCSK9, Lipoprotein receptors, and Atherosclerosis
PCSK9、脂蛋白受体和动脉粥样硬化
- 批准号:
8248701 - 财政年份:2011
- 资助金额:
$ 33.98万 - 项目类别:
PCSK9, Lipoprotein receptors, and Atherosclerosis
PCSK9、脂蛋白受体和动脉粥样硬化
- 批准号:
8606492 - 财政年份:2011
- 资助金额:
$ 33.98万 - 项目类别:
PCSK9, Lipoprotein receptors, and Atherosclerosis
PCSK9、脂蛋白受体和动脉粥样硬化
- 批准号:
8131556 - 财政年份:2011
- 资助金额:
$ 33.98万 - 项目类别:
PCSK9, Lipoprotein receptors, and Atherosclerosis
PCSK9、脂蛋白受体和动脉粥样硬化
- 批准号:
8436303 - 财政年份:2011
- 资助金额:
$ 33.98万 - 项目类别:
MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
APOAI 和动脉粥样硬化的巨噬细胞表达
- 批准号:
6191927 - 财政年份:2000
- 资助金额:
$ 33.98万 - 项目类别:
MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
APOAI 和动脉粥样硬化的巨噬细胞表达
- 批准号:
6390892 - 财政年份:2000
- 资助金额:
$ 33.98万 - 项目类别:
相似海外基金
Biogenesis and Catabolism of Atherogenic Lipoproteins
致动脉粥样硬化脂蛋白的生物发生和分解代谢
- 批准号:
10628985 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Identification of plasma lipoprotein proteins and lipids as biomarkers of innate-immunity and vascular contributions to Alzheimer's disease and Alzheimer's disease-related dementias in older adults
鉴定血浆脂蛋白和脂质作为老年人阿尔茨海默病和阿尔茨海默病相关痴呆的先天免疫和血管贡献的生物标志物
- 批准号:
10660037 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Regulation of plasma LDL and HDL by microRNA-541-3p
microRNA-541-3p 对血浆 LDL 和 HDL 的调节
- 批准号:
10733641 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial
奥利司他治疗 1 型高脂蛋白血症的长期疗效和安全性:一项随机、双盲、安慰剂对照试验
- 批准号:
10570530 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Adipose MTP and FIT2 in the regulation of plasma lipids, obesity and atherosclerosis
脂肪MTP和FIT2在血脂、肥胖和动脉粥样硬化调节中的作用
- 批准号:
10628990 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Human Tissues, Lipidomics, and Proteomics Core
人体组织、脂质组学和蛋白质组学核心
- 批准号:
10628988 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
The role of FIT2 in VLDL assembly, hepatic triglyceride homeostasis, and lipoprotein atherogenicity
FIT2 在 VLDL 组装、肝甘油三酯稳态和脂蛋白致动脉粥样硬化中的作用
- 批准号:
10638637 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别: